Presenting clinical data and Ikaros isoform expression in children with AML
| Case . | Age . | Sex . | WBC count onset (per ML) . | Percentage of blasts . | FAB . | Karyotype . | Positive immunologic markers . | Ikaros isoforms expressed* . |
|---|---|---|---|---|---|---|---|---|
| 1 | 5 y 6 mo | F | 5 600 | 58 | M2 | 45,X t(8;13)(q22;q34) | CD13, 56, HL-DR | Ik2 |
| 2 | 5 y 10 mo | F | 19 100 | 44 | M2 | 46,XX, t(8;21) | CD7, 19, 34, HL-DR | Ik2 |
| 3 | 13 y 6 mo | F | 19 400 | 84 | M2 | 46,XX, t(8;21) | CD2, 13, 14, 15, 33, 11b | Ik1, 2 |
| 4 | 6 y 6 mo | F | 9 500 | 40 | M2 | 46,XX, t(8;21) | CD7, 19, 33, 34 | Ik1, 2 |
| 5 | 9 y 1 mo | F | 15 400 | 36 | M2 | 46,XX, t(8;21) | CD13, 19, 33, 34, HL-DR | Ik1, 2 |
| 6 | 8 y | M | 10 100 | 67 | M2 | 45,X, −Y, t(8;21)(q22;q22) | CD15, 33, 34, HL-DR | Ik1, 2 |
| 7 | 7 y 4 mo | F | 6 200 | 26 | M2 | 45, X, −X, t(8;21) | CD19, 15, 34, HL-DR | Ik2 |
| 8 | 4 y | M | 7 300 | 29 | M2 | 46,XY, t(8;21)(q22;q22) | CD13, 33, 34, 11b | Ik1, 2 |
| 9 | 7 mo | F | 278 000 | 47 | M4 | 46,XX | CD13, 14, 15, 33, 11b | Ik2, 6 |
| 10 | 13 y 6 mo | F | 4 000 | 53 | M4 | 46,XX | CD7, 15, 33, 11b | Ik6 |
| 11 | 10 y 1 mo | M | 164 700 | 91 | M4 | 46,XY, inv(16)(p13;q22) | CD13, 15, 33, 34 | Ik6 |
| 12 | 10 y 1 mo | F | 174 700 | 81 | M4 | 46,XX,inv(9)(p11;q13), inv(6)(p13;q22) | CD2, 19, 33, 34, 11b | Ik6 |
| 13 | 14 y | M | 8 000 | 78 | M4 | 47,Y,add(X)(p22),add(3)(p25),−17, others | CD4, 7, 13, 15, 33, HL-DR | Ik2 |
| 14 | 10 y 1 mo | M | 95 900 | 93 | M4 | 46,XY | CD4, 15, 33, 34, 11b | Ik1, 2 |
| 15 | 4 y | F | 2 900 | 79 | M5a | 50,XXX, +6, +8, +18, del(11)(q21;q23) | CD5, 56 | Ik1, 2, 6 |
| 16 | 2 y 1 mo | M | 20 000 | NA | M5a | 48,XY, +8, +9, t(9;11)(p22;q23) | CD4, 15, 33 | Ik1, 2 |
| 17 | 14 y 2 mo | F | 16 800 | 64 | M5b | 47,XX, +21 | CD7, 13, 34, 38, HL-DR | Ik2, 6 |
| 18 | 13 y 6 mo | F | 900 | 7 | M5b | 47,XX, +8, t(9;11)(p22;q23) | NE | Ik6 |
| 19 | 11 mo | F | 25 000 | 50 | M7 | 46,XX | CD19, 33, 34, 41a, 41b, 42a | Ik1, 2 |
| 20 | 1 y 7 mo | M | 30 800 | 35 | M7 | 46,XY, t(6;22;17)(p23,q11,q12) | CD10, 11b | Ik1, 2 |
| 21 | 2 y 2 mo | M | 3 500 | 83 | M7 | 47,Y, −X, t(4;11)(q21,q23) | CD56, PPO | Ik1, 2 |
| 22 | 10 mo | M | 20 200 | 48 | M7 | 48, XY, +8, +19 | CD4, 33, 41a, 41b, 42a | Ik1, 2 |
| 23 | 1 y 9 mo | M | 7 800 | 40 | M7 | NE | CD2, 7, 13, 38, 11b | Ik1, 2 |
| 24 | 2 y | M | 15 800 | 38 | M7 | 46,XY, t(16;21) | CD13, 34, HL-DR, 11c | Ik1, 2 |
| Case . | Age . | Sex . | WBC count onset (per ML) . | Percentage of blasts . | FAB . | Karyotype . | Positive immunologic markers . | Ikaros isoforms expressed* . |
|---|---|---|---|---|---|---|---|---|
| 1 | 5 y 6 mo | F | 5 600 | 58 | M2 | 45,X t(8;13)(q22;q34) | CD13, 56, HL-DR | Ik2 |
| 2 | 5 y 10 mo | F | 19 100 | 44 | M2 | 46,XX, t(8;21) | CD7, 19, 34, HL-DR | Ik2 |
| 3 | 13 y 6 mo | F | 19 400 | 84 | M2 | 46,XX, t(8;21) | CD2, 13, 14, 15, 33, 11b | Ik1, 2 |
| 4 | 6 y 6 mo | F | 9 500 | 40 | M2 | 46,XX, t(8;21) | CD7, 19, 33, 34 | Ik1, 2 |
| 5 | 9 y 1 mo | F | 15 400 | 36 | M2 | 46,XX, t(8;21) | CD13, 19, 33, 34, HL-DR | Ik1, 2 |
| 6 | 8 y | M | 10 100 | 67 | M2 | 45,X, −Y, t(8;21)(q22;q22) | CD15, 33, 34, HL-DR | Ik1, 2 |
| 7 | 7 y 4 mo | F | 6 200 | 26 | M2 | 45, X, −X, t(8;21) | CD19, 15, 34, HL-DR | Ik2 |
| 8 | 4 y | M | 7 300 | 29 | M2 | 46,XY, t(8;21)(q22;q22) | CD13, 33, 34, 11b | Ik1, 2 |
| 9 | 7 mo | F | 278 000 | 47 | M4 | 46,XX | CD13, 14, 15, 33, 11b | Ik2, 6 |
| 10 | 13 y 6 mo | F | 4 000 | 53 | M4 | 46,XX | CD7, 15, 33, 11b | Ik6 |
| 11 | 10 y 1 mo | M | 164 700 | 91 | M4 | 46,XY, inv(16)(p13;q22) | CD13, 15, 33, 34 | Ik6 |
| 12 | 10 y 1 mo | F | 174 700 | 81 | M4 | 46,XX,inv(9)(p11;q13), inv(6)(p13;q22) | CD2, 19, 33, 34, 11b | Ik6 |
| 13 | 14 y | M | 8 000 | 78 | M4 | 47,Y,add(X)(p22),add(3)(p25),−17, others | CD4, 7, 13, 15, 33, HL-DR | Ik2 |
| 14 | 10 y 1 mo | M | 95 900 | 93 | M4 | 46,XY | CD4, 15, 33, 34, 11b | Ik1, 2 |
| 15 | 4 y | F | 2 900 | 79 | M5a | 50,XXX, +6, +8, +18, del(11)(q21;q23) | CD5, 56 | Ik1, 2, 6 |
| 16 | 2 y 1 mo | M | 20 000 | NA | M5a | 48,XY, +8, +9, t(9;11)(p22;q23) | CD4, 15, 33 | Ik1, 2 |
| 17 | 14 y 2 mo | F | 16 800 | 64 | M5b | 47,XX, +21 | CD7, 13, 34, 38, HL-DR | Ik2, 6 |
| 18 | 13 y 6 mo | F | 900 | 7 | M5b | 47,XX, +8, t(9;11)(p22;q23) | NE | Ik6 |
| 19 | 11 mo | F | 25 000 | 50 | M7 | 46,XX | CD19, 33, 34, 41a, 41b, 42a | Ik1, 2 |
| 20 | 1 y 7 mo | M | 30 800 | 35 | M7 | 46,XY, t(6;22;17)(p23,q11,q12) | CD10, 11b | Ik1, 2 |
| 21 | 2 y 2 mo | M | 3 500 | 83 | M7 | 47,Y, −X, t(4;11)(q21,q23) | CD56, PPO | Ik1, 2 |
| 22 | 10 mo | M | 20 200 | 48 | M7 | 48, XY, +8, +19 | CD4, 33, 41a, 41b, 42a | Ik1, 2 |
| 23 | 1 y 9 mo | M | 7 800 | 40 | M7 | NE | CD2, 7, 13, 38, 11b | Ik1, 2 |
| 24 | 2 y | M | 15 800 | 38 | M7 | 46,XY, t(16;21) | CD13, 34, HL-DR, 11c | Ik1, 2 |
NA indicates not available; NE, not examined.
Determined by RT-PCR.